Get the Stockscreener App
64.49
2.41%
-1.5488
Incyte Corp stock is traded at $64.49, with a volume of 853.55K.
It is down -2.41% in the last 24 hours and up +2.86% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$66.04
Open:
$65.71
24h Volume:
853.55K
Relative Volume:
0.45
Market Cap:
$12.48B
Revenue:
$4.41B
Net Income/Loss:
$21.27M
P/E Ratio:
201.54
EPS:
0.32
Net Cash Flow:
$288.81M
1W Performance:
+0.32%
1M Performance:
+2.86%
6M Performance:
-13.59%
1Y Performance:
+12.48%
1-Day Range:
$63.93
$65.77
1-Week Range:
$63.93
$66.26
52-Week Range:
$53.56
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
64.47 | 12.49B | 4.41B | 21.27M | 288.81M | 0.32 |
|
ONC
Beone Medicines Ltd Adr
|
240.39 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.65 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
79.56 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.13 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Vitiligo Market Growth Trends and Forecast Report 2025-2033Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access - Yahoo Finance
Incyte (NASDAQ:INCY) Price Target Raised to $73.00 at Truist Financial - Defense World
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential - Investing.com
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential By Investing.com - Investing.com India
Incyte to Present at Upcoming Investor Conference on Monday, June 9, 2025 at 11:20 am (ET) - BioSpace
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Incyte (INCY) Target Price Raised by Truist Securities | INCY St - GuruFocus
Incyte (INCY) Sees Price Target Boost from Truist Analyst | INCY Stock News - GuruFocus
Incyte to Present at Upcoming Investor Conference - Yahoo Finance
Incyte Co. (NASDAQ:INCY) Shares Bought by Cetera Investment Advisers - Defense World
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
FDA approves Incyte’s retifanlimab combo for SCAC treatment - Yahoo Finance
Is Wall Street Bullish or Bearish on Incyte Stock? - inkl
Is Wall Street Bullish Or Bearish On Incyte Stock? - Barchart.com
Incyte Gets FDA Approval for Zynyz in New Cancer Indication - MSN
Incyte adds more FDA approvals for Zynyz in cancer - BioWorld MedTech
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Trea - GuruFocus
Incyte granted FDA approval of Zynyz for SCAC - The Pharma Letter
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval - BioSpace
No Article III Appellate Standing Under the Sun - Lexology
FDA Broadens Approval for Incyte's Zynyz in Cancer Treatments (I - GuruFocus
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Treatment | INCY Stock News - GuruFocus
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States | INCY Stock News - GuruFocus
FDA approves new anal cancer treatment Zynyz by Incyte - Investing.com
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States – Company AnnouncementFT.com - Financial Times
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - The Joplin Globe
Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show - Law.com
Incyte Corporation (INCY) Reaches Settlement with Novartis Over Royalty Dispute - GuruFocus
Incyte (INCY) Reaches $280M Settlement with Novartis Over Jakafi Royalties - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Incyte settles royalty dispute with Novartis for $280 million - Investing.com
Incyte at Bank of America Conference: Strategic Insights on Growth - Investing.com
Incyte To Present At 2025 BofA Securities Health Care Conference; Webcast At 4:40 PM ET - Nasdaq
Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance - Yahoo Finance
Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating! - Smartkarma
Steroid Refactory Acute Graft-Versus-Host Disease Market Set - openPR.com
Incyte Co. (NASDAQ:INCY) Holdings Raised by Stifel Financial Corp - Defense World
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News
Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
William Blair Has Optimistic Outlook of Incyte Q4 Earnings - Defense World
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):